Wilke, Thomas - In: The Patient: Patient-Centered Outcomes Research 2 (2009) 1, pp. 39-49
<Emphasis Type="Bold">Background: Since 2008, the availability of the oral direct thrombin inhibitor dabigatran etexilate provides a further therapeutic alternative to injectable low-molecular-weight heparin (LMWH) for thromboprophylaxis following hip or knee replacement surgery. The intention of this study is to...</emphasis>